| |  Online-Ressource |
|---|
| Verfasst von: | Jagadeeshan, Sankar [VerfasserIn]  |
|---|
| | Novoplansky, Ofra Z. [VerfasserIn] |
|---|
| | Cohen, Oded [VerfasserIn] |
|---|
| | Kurth, Ina [VerfasserIn] |
|---|
| | Heß, Jochen [VerfasserIn] |
|---|
| | Rosenberg, Ari J. [VerfasserIn] |
|---|
| | Grandis, Jennifer R. [VerfasserIn] |
|---|
| | Elkabets, Moshe [VerfasserIn] |
|---|
| Titel: | New insights into RAS in head and neck cancer |
|---|
| Verf.angabe: | Sankar Jagadeeshan, Ofra Z. Novoplansky, Oded Cohen, Ina Kurth, Jochen Hess, Ari J. Rosenberg, Jennifer R. Grandis, Moshe Elkabets |
|---|
| E-Jahr: | 2023 |
|---|
| Jahr: | November 2023 |
|---|
| Umfang: | 24 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Online verfügbar: 22. August 2023, Artikelversion: 31. August 2023 ; Gesehen am 07.12.2023 |
|---|
| Titel Quelle: | Enthalten in: Biochimica et biophysica acta / Reviews on cancer |
|---|
| Ort Quelle: | Amsterdam : Elsevier, 1974 |
|---|
| Jahr Quelle: | 2023 |
|---|
| Band/Heft Quelle: | 1878(2023), 6 vom: Nov., Artikel-ID 188963, Seite 1-24 |
|---|
| ISSN Quelle: | 1879-2561 |
|---|
| Abstract: | RAS genes are known to be dysregulated in cancer for several decades, and substantial effort has been dedicated to develop agents that reduce RAS expression or block RAS activation. The recent introduction of RAS inhibitors for cancer patients highlights the importance of comprehending RAS alterations in head and neck cancer (HNC). In this regard, we examine the published findings on RAS alterations and pathway activations in HNC, and summarize their role in HNC initiation, progression, and metastasis. Specifically, we focus on the intrinsic role of mutated-RAS on tumor cell signaling and its extrinsic role in determining tumor-microenvironment (TME) heterogeneity, including promoting angiogenesis and enhancing immune escape. Lastly, we summarize the intrinsic and extrinsic role of RAS alterations on therapy resistance to outline the potential of targeting RAS using a single agent or in combination with other therapeutic agents for HNC patients with RAS-activated tumors. |
|---|
| DOI: | doi:10.1016/j.bbcan.2023.188963 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.bbcan.2023.188963 |
|---|
| | Volltext: https://www.sciencedirect.com/science/article/pii/S0304419X23001129 |
|---|
| | DOI: https://doi.org/10.1016/j.bbcan.2023.188963 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Head and neck cancer |
|---|
| | Metastasis |
|---|
| | Pre-clinical and clinical targeting |
|---|
| | Progression |
|---|
| | RAS activation |
|---|
| | Therapy resistance |
|---|
| K10plus-PPN: | 1872275893 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
New insights into RAS in head and neck cancer / Jagadeeshan, Sankar [VerfasserIn]; November 2023 (Online-Ressource)
